This is the first case presenting a rare coexistence of a novel ALK double fusion, namely, ELMOD3-ALK and EML4-ALK, in a patient with lung adenocarcinoma who demonstrated favorable sensitivity to alectinib. Here, ALK is linked to lung adenocarcinoma.